Articles tagged with Molecular Targets
Researchers investigated why bones become less responsive to exercise with age, finding increased mtROS or decreased Atg7-dependent autophagy in osteoblastic cells do not contribute to reduced mechanoresponsiveness. Damage to the bone's osteocyte network also does not prevent a healthy bone-building response.
Isowalsuranolide activates autophagy-dependent cell death by targeting TrxR1/2, leading to ROS-mediated lysosomal biogenesis and reduced cell growth. The study reveals the TrxR1/2-p53-TFEB/TFE3 axis as a key regulator of cellular homeostasis in cancer.
A promising new target for a Lyme disease vaccine has emerged: the Lyme bacterial protein CspZ. Genetic engineering revealed hidden regions that trigger a strong immune response. The modified protein promotes continuous production of protective antibodies, reducing the need for booster shots.
Researchers have isolated three new bitter compounds from the mushroom Amaropostia stiptica and found that one of them, oligoporin D, stimulates a specific human bitter taste receptor type at very low concentrations. This discovery expands knowledge of natural bitter compounds and their receptors, which could lead to new applications i...
Researchers found that combining imipridones with radiation therapy and temozolomide slowed glioblastoma growth and prolonged survival in mice. The treatment also boosted immune responses and suppressed MGMT protein expression, making it more effective.
Researchers have developed drug-delivering aptamers that target and kill leukemia stem cells, reducing the need for high doses of chemotherapy. The aptamers pair well with existing drugs like daunorubicin to deliver a targeted one-two knockout punch against cancer.
Researchers at MIT have developed a method to mass manufacture nanoparticles that target cancer cells, eliminating the need for manual polymer mixing and streamlining production. This approach integrates good manufacturing practice (GMP)-compliant processes, making it suitable for large-scale production of cancer treatments.
Cleveland Clinic researchers successfully tested quantum computing's ability to simulate proton affinity, a fundamental chemical process critical to life. The study used machine learning applications on quantum hardware, achieving higher accuracy than classical computing in predicting proton affinity.
Researchers have developed a new approach to personalize treatments for young cancer patients by growing tumors in chicken eggs and analyzing proteins. The technique, which combines genomics and proteomics, was successful in identifying a treatment option for a patient with a rare pediatric cancer.
Researchers at Cornell University discovered that the FGR protein can induce cell differentiation in leukemia cells similar to retinoic acid treatment. The presence of FGR alone was enough to make these cells mature, producing well-known markers of maturation and expressing inhibitor of the cell cycle p27.
The SUMMIT trial shows tirzepatide reduces the risk of cardiovascular death or worsening heart failure in patients with obesity, chronic kidney disease, and heart failure, while improving kidney function. Researchers found significant improvements in both patient groups with and without chronic kidney disease.
Researchers from Prof. Yardena Samuels's lab developed a new approach to cancer treatment by manipulating cancer cells to produce dozens of suspicious proteins, leading to a powerful immune response that destroys human cancer cells and slows tumor growth in mouse models.
Researchers discovered TBX2 drives therapy resistance by shifting signaling from the androgen receptor to the glucocorticoid receptor. The study identified a strategy to target this switch, potentially predicting patient risk and offering new treatment approaches.
Researchers found that digital PCR for BCR::ABL1 is more sensitive and accurate than conventional real-time quantitative PCR to detect ultralow levels of residual leukemic disease. The technology enabled the detection of stable deep molecular remission in 97% of patients, allowing for safe discontinuation of treatment.
Researchers developed a sensor platform that tracks multiple metabolites continuously, offering a window into disease onset and health status. The technology harnesses natural biochemical processes, enabling reliable detection of over 800 metabolites, with potential applications in diagnosing metabolic disorders and optimizing fitness.
Researchers at Vanderbilt University Medical Center discovered how C. diff converts a poisonous compound into a usable nutrient, increasing its competitive advantage in the infected gut. The findings point to novel therapeutic strategies, including targeting the TudS enzyme to preserve healthy gut microbiota.
Researchers mapped m6A patterns across 162 prostate cancer tumors and found that these modifications were closely tied to tumor aggressiveness. Analyzing m6A tags could help doctors predict disease behavior and determine personalized treatment strategies for patients with prostate cancer.
A new review article identifies major themes in AI application to neurosciences, including a 5-fold increase in AI-related publications. The study also notes a surge of over 13-fold in clinical neurology AI-related publications in the past decade.
Scientists have discovered peptides that bind irreversibly to the transcription factor cJun, permanently blocking its action in cancer cells. The study uses a new screening platform technology and has shown promising results for developing new cancer treatments.
Researchers at St. Jude Children's Research Hospital found that removing the 'signal jammer' protein VDAC2 can improve how tumors respond to immunotherapy. This breakthrough could lead to new ways to enhance immunotherapies and make them more effective in treating resistant cancers.
Researchers studied male mouse brain activity during sex to understand the dynamics of neurotransmitters dopamine and acetylcholine. The study revealed that these chemicals control the progression of sexual behavior, with dopamine release slowing down before quick rise during ejaculation.
The Chinese Medical Association has released updated guidelines for pediatric mycoplasma pneumoniae infection, emphasizing a multi-faceted diagnostic approach and evidence-based treatment strategies. The guidelines highlight the importance of accurate diagnosis and responsible antibiotic use to combat rising resistance.
Dr. Owen Witte has been awarded the 12th annual Harrington Prize for Innovation in Medicine for his groundbreaking work on leukemia, lymphoma, and other cancers. His discoveries have led to life-saving therapies like Gleevec and ibrutinib, transforming cancer treatment.
Researchers created a powerful new computational and artificial intelligence tool that can generate high-resolution 3D maps of the brain in mice, allowing users to zoom in and out and peer into the full set of molecules producing energy for brain functions. This breakthrough brings scientists closer to understanding the role of metabol...
Researchers at the University of Zurich have developed a technology to test 25 antibodies simultaneously in a single mouse, greatly reducing the number of laboratory animals required. The method uses protein fragments as barcodes for analysis, allowing for high-quality preclinical data on multiple antibody candidates.
The WIN Consortium is transforming cancer care through personalized medicine, leveraging AI, molecular profiling, and clinical trials. The organization's innovations, including N-of-1 clinical trials and WINTHER and WINGPO trials, are helping clinicians make more precise treatment decisions and improving outcomes for cancer patients.
Researchers have identified distinct protein degradation patterns in key brain regions for individuals who witnessed trauma, differing from those who experienced it firsthand. Sex-specific differences also emerge, with implications for targeted treatments and a better understanding of PTSD development.
Researchers developed CeSPIACE, a 39-amino-acid peptide drug candidate that binds to the spike protein, blocking viral entry. It demonstrates strong binding to major SARS-CoV-2 variants and shows efficacy against multiple strains in vivo and in vitro experiments.
Senescent cells can cause chronic inflammation through the secretion of inflammatory molecules, leading to age-related diseases. The study found that a cellular circuit controlling DNA repair can suppress this inflammation, offering potential ways to promote healthier aging.
The study found that Black patients have a higher prevalence of PD-L1 overexpression, TP53 mutations, and KRASG12R mutations compared to White patients. This could affect how their cancer progresses and responds to treatment.
A UMass Amherst Ph.D. student has been awarded a €20,000 grant to investigate a new therapeutic target for Lyme disease by targeting the GuaB enzyme necessary for Borrelia burgdorferi replication in mammals.
The study highlights the role of the Nwd1 gene in liver disease and its potential as a therapeutic target. Mice with Nwd1 gene deletion exhibited liver pathologies mirroring MASH, including excessive lipid accumulation and increased ER stress.
Researchers found that PRP treatment increased gene expression related to metabolism, cell survival, and communication between cells in cumulus cells. This suggests that PRP may help support egg development and fertility in women with poor ovarian response.
A new Northwestern University study found that enhancing the brain's immune cells can clear Alzheimer's plaques and restore a healthier brain environment in immunized patient brains. The findings could reshape the future of Alzheimer's treatments by shifting the focus from removing plaques to harnessing the brain's natural defenses.
Researchers at the University of Missouri have identified a small molecule drug that targets a specific serotonin receptor, showing promise as a treatment for sarcopenia. The study suggests that this neurotherapeutic can improve muscle strength by activating motor neurons to fire more effectively.
Researchers developed a nanoparticle that delivers an mRNA vaccine targeting a KRAS antigen, boosting the immune response against pancreatic cancer. Experiments in mice showed inhibited and prevented tumor growth, as well as long-term protection against recurrence.
The Damon Runyon Cancer Research Foundation has named 13 new Fellows, awarding them $300,000 each to investigate cancer causes and mechanisms. Five recipients of the Dale F. Frey Award for Breakthrough Scientists will also receive an additional $100,000 investment to catapult their research careers.
PARP inhibitors have been found to be effective in treating cancers with BRCA1/2 mutations by blocking DNA repair pathways. The combination of PARPis with chemotherapeutic drugs can also improve treatment efficacy, increasing DNA damage and blocking repair processes.
Researchers discover engineered TIMP molecules can block cancer cell migration and invasion, offering a targeted approach to treating GBM. The findings also suggest the potential for safe treatment with minimal side effects.
A new study reveals that radiotherapy has opposite effects on glioblastoma multiforme (GBM) and low-grade gliomas (LGG), with GBM patients living longer after treatment. The study highlights the need for personalized treatment approaches based on genetic and molecular characteristics to improve survival outcomes.
The collaboration combines Insilico's Pharma.AI platform with Tenacia's expertise in CNS biology and clinical development. By leveraging generative AI, the partnership seeks to expand therapeutic options and enhance outcomes for patients worldwide. Recent successes by Insilico include the nomination of ISM8969, a BBB penetrable NLRP3 i...
Researchers discovered that erucamide inhibits Type III Secretion injectisome assembly in Gram-negative bacteria, enhancing plant immunity and reducing disease susceptibility. Exogenous application of erucamide protects crops from bacterial diseases, offering a potential biopesticide for sustainable agriculture.
A research team at the University of Cologne has identified a specific form of the tau protein, 1N4R, responsible for mediating toxic effects of protein clumps in human brain cells. This breakthrough understanding could lead to new treatments for Alzheimer's disease.
Key molecular applications in diagnosing and managing hematopoietic and lymphocytic neoplasms include comprehensive mutational profiling, aiding accurate diagnosis and prognostication. The use of targeted therapies against specific genetic abnormalities further refines treatment selection.
Researchers have developed a palladium-mediated reaction to precisely modify peptides and proteins, overcoming challenges in bioconjugation. The method targets dehydroalanine-containing peptides and proteins, enabling efficient synthesis of structurally unique peptides.
UTA's expansion of its undergraduate research program has enabled students to present their work at major symposiums, including the American Institute of Aeronautics and Astronautics conference. The program has strengthened students' commitment to pursuing graduate studies in various fields.
Insilico Medicine has discovered a potent and selective CDK12/13 dual inhibitor, compound 12b, using AI-powered platforms. The compound shows significant efficacy in breast cancer and AML models without inducing side effects, paving the way for further therapeutic development.
The ESMO Targeted Anticancer Therapies Congress 2025 features state-of-the-art presentations on new targets, tumour-agnostic drug development, and the role of artificial intelligence in cancer treatment. The congress also highlights recent study results and their potential impact on precision medicine.
Researchers studied mRNA length variations during atherosclerosis progression in mice, discovering shorter mRNAs as the disease advances. The findings suggest alternative splicing mechanisms may play a role in generating diverse mRNA sequences related to the disease.
A groundbreaking study using AI-driven robotics laboratory identifies Rentosertib, a potent TNIK inhibitor, as a highly effective senomorphic agent capable of reducing aging-related markers. The study reveals TNIK inhibition alleviates key signaling pathways implicated in senescence and fibrosis.
Researchers have discovered double negative memory B cells, a novel subset of immune cells that are more dysfunctional when in close contact with tumors. These cells may be a useful diagnostic marker and a potential target for developing new immunotherapies.
Researchers at U of T discover a ginger compound called furanodienone that selectively binds to and regulates nuclear receptor PXR, reducing inflammation in the colon. FDN has been shown to increase tight junction proteins, repairing damage to the gut lining caused by inflammation.
Researchers at UCSF have identified unique, cancer-specific proteins created through mistakes in RNA splicing. These antigens could be used to create potent immunotherapies that recognize and attack hard-to-treat tumors. The discovery offers new hope for glioma patients and expands the number of targets available for cancer therapy.
A study found that pro-inflammatory molecules contribute to benign prostatic hyperplasia (BPH) in aging men, especially those with metabolic syndrome. Men with BPH had higher levels of pro-inflammatory markers and lower anti-inflammatory substances, suggesting a link between inflammation and prostate conditions.
ABT-263 eliminates harmful aging cells in the gut, reducing inflammation and lowering cancer risk in a mouse model of GI cancer. The study suggests that removing senescent cells could help prevent radiation-related GI cancer, highlighting the potential of senolytic drugs as a preventive treatment.
Researchers at Pusan National University have developed a novel drug delivery system that uses nanoparticles to target and kill colorectal cancer cells. The system, which involves encapsulating cancer cell-activated nanoconjugates in an alginate matrix, can selectively deliver drugs to tumor cells while minimizing side effects.
A team of researchers from the University of Arizona College of Medicine – Tucson found that an FDA-approved osteoporosis treatment, risedronate, can correct a gene mutation and normalize heart function in animal models. The study provides hope for treating other rare diseases using precision treatments tailored to individual mutations.
A preclinical study reveals that tumors drive clot formation by releasing chemokines, prompting immune cells to release small vesicles that attach to cell fragments, forming life-threatening clots. The findings may lead to diagnostic tests and safer therapies to target the root of blood clotting risk.
A team from Tokyo University of Science developed a novel trivalent platform for triple click chemistry, allowing for the efficient synthesis of complex compounds. The approach utilizes simple initial materials and promotes sustainable pharmaceutical synthesis.
Researchers discovered that mismatch repair genes are critical in eliciting damages to neurons vulnerable to Huntington's disease, triggering downstream pathologies and motor impairment. Targeting these genes may offer novel therapeutic approaches, including improving locomotor and gait deficits and reducing neuronal cell death.